Please assess the completion status of the following clinical trial:

Trial Title: A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced renal cell carcinoma with histology confirmation~* Grade III/IV AEs happen during first cycle of sunitinib 50mg/day 4 weeks on followed by 2 weeks of rest~* ECOG performance status 0 or 1~* Appropriate vital organ functions~Exclusion Criteria:~* Prior systemic treatment of mRCC~* Patients treated with any neoadjuvant or adjuvant systemic therapy~* Major surgery \<4 weeks or radiation therapy \<2 weeks of starting the study treatment. Prior palliative radiotherapy to metastatic lesion(s) is permitted, provided there is at least one measurable lesion that has not been irradiated~* Pregnant~* Allergic history to sunitinib

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sunitinib (Type: EXPERIMENTAL): Sunitinib malate, 12.5mg/capsule, 50mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).